Pfizer

Pfizer beats Q1 profit estimates on cost cut, strong sale of heart drug

It reported total revenue of $13.70 billion for the first quarter, compared with analysts' expectations of $13.91 billion, according to LSEG data

Pfizer ends development of promising obesity pill after safety concerns

According to the company's latest statement, one patient experienced a potential liver injury that may have been caused by the drug

US prosecutors investigate tip about timing of Pfizer's Covid vaccine

The report said on Wednesday GSK's former head of vaccine development, Philip Dormitzer, had told his colleagues about the delay by Pfizer, where he worked before joining the British company

China's vice premier reassures foreign CEOs on investment, business growth

China reassures foreign investors amid geopolitical tensions, urging open markets and promising a better business environment at the China Development Forum

Pfizer's breast cancer drug Vepdegestrant posts mixed results in key trial

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its goals for a subset who have a specific genetic mutation

Pfizer may move outside manufacturing plants to US: CEO amid tariff threats

The US president has imposed a 10 per cent tariff across all Chinese imports into the US and proposed a 25 per cent levy on most goods from Mexico and Canada

Pfizer shares gain 9% after board approves agreement with Mylan Pharma

Under the agreement, the company with Mylan Pharma will market and sell two brands Ativan and Pacitane. The contract is for five years within the territory of India

Pfizer beats profit estimates on heart disease drug, Covid vaccine sales

Pfizer is facing investor pressure to show that its recent acquisitions and investments can bring in returns

Pfizer Q3 results: Net profit falls 2% to Rs 128 cr, revenue at Rs 538 cr

Drug firm Pfizer on Friday said its net profit declined by 2 per cent to Rs 128 crore for the third quarter ended December 31, 2024. The company had reported a net profit of Rs 130 crore in the October-December period of last fiscal. Revenue from operations declined to Rs 538 crore in the third quarter as compared with Rs 540 crore in the year-ago period, Pfizer Ltd said in a regulatory filing. Shares of the company on Friday ended 0.43 per cent up at Rs 4,536.05 apiece on BSE.

Nifty outlook indecisive, says Vinay Rajani; picks 2 stocks to buy today

Stocks to Buy Today: Narayana Hrudalaya and Pfizer shares have been rising with heavy volumes

In relief for investors, Pfizer 2025 profit forecast in line with estimates

Shares of the drugmaker rose nearly 3 per cent to $25.98 in premarket trading after the company also said it was expecting 2025 sales of its Covid-19 vaccine and drug to be consistent

Ex Pfizer CEO, CFO not to involve in Starboard's campaign on drugmaker

Pfizer's shares have fallen more than 9% in the past year and trade at around half of their pandemic-era highs as sales of its COVID products shrink

Activist investor Starboard Value acquires $1 billion stake in Pfizer

Read served as CEO until Albert Bourla took the position in 2019. Bourla was instrumental in working with BioNTech to develop a COVID-19 vaccine

Activist investor Starboard Value takes $1 billion stake in Pfizer

Starboard has also approached Ian Read, a former Pfizer CEO, and Frank D'Amelio, who served as CFO until 2021, and both have expressed interest in helping the activist investor

Pfizer to further reduce stake in Haleon, offers to sell 540 million share

The US company intends to sell 540 million Haleon shares, according to a statement on Monday

Pfizer surges 3% as investors cheer 350% dividend announcement; details

The northward movement in the rally follows the announcement of a whopping 350 per cent dividend, or Rs 35 per share, for FY24

GSK wins latest trial on cancer claims for heartburn drug Zantac: Official

The companies collectively are facing thousands of lawsuits against them in courts across the United States

Pfizer raises annual profit forecast on strong sales of cancer, heart drugs

The market for pharmaceutical products used in managing Covid-19 has shrunk by billions of dollars a year, including for Pfizer's vaccines and treatments

Tamil Nadu emerges as GCC magnet, pharma major AstraZeneca leads the charge

Not just AstraZeneca, but Pfizer and Roche have also set up their centres in the state

Pfizer, Moderna Covid vaccine patents battle to continue after UK ruling

Moderna had argued Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the Covid-19 pandemic began in late 2019